Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.

Please visit answersincme.com/CQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology provides a comprehensive update on the evidence-based use of targeted systemic therapies in pediatric patients with moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when initiation of systemic therapy may be warranted in pediatric patients with moderate-to-severe atopic dermatitis (AD); Describe the clinical profiles of targeted systemic therapies that are approved for pediatric patients with moderate-to-severe AD; and Outline patient-centered strategies to enhance long-term outcomes for pediatric patients with moderate-to-severe AD who are candidates for targeted systemic therapies.

Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand and foot dermatitis; and Outline future treatment considerations to optimize the use of novel systemic therapies in patients with moderate-to-severe atopic hand and foot dermatitis.

Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC; Review the latest evidence on the efficacy and safety of emerging neoadjuvant immunotherapies for patients with surgically resectable CSCC; and Outline clinical strategies to optimize the therapeutic management of surgically resectable CSCC for patients who would be appropriate candidates for neoadjuvant immunotherapies.

Please visit answersincme.com/ZUU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology and oncology discusses the clinical implications of approved and emerging anti–lymphocyte activation gene-3 (LAG-3)/programmed cell death protein 1 (PD-1) combinations in advanced melanoma. Upon completion of this activity, participants should be better able to: Outline the current unmet treatment needs for patients with advanced melanoma; Review the mechanism of action of anti–LAG-3/PD-1 combinations for the management of advanced melanoma; and Recognize the clinical impact of approved and emerging anti–LAG-3/PD-1 combinations as a therapeutic strategy for the treatment of advanced melanoma.

Please visit answersincme.com/DNA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and dermatology discuss therapeutic options in the first-line treatment of advanced melanoma and the role of the multidisciplinary team in maximizing treatment outcomes. Upon completion of this activity, participants should be better able to: Identify the unmet clinical needs for patients with advanced melanoma; Describe the guideline-recommended first-line treatment strategies for patients with advanced melanoma; and Outline a multidisciplinary, evidence-based therapeutic plan that elevates the efficacy and safety of treatment for patients with advanced melanoma.

Please visit answersincme.com/BRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging strategies to optimize the multidisciplinary care of advanced basal cell carcinoma (BCC) with immunotherapy.Upon completion of this activity, participants should be better able to: Identify patients with BCC for whom a second-line immunotherapy regimen would be appropriate; Review the clinical profiles of immunotherapy-based regimens for the second-line treatment of advanced BCC; and Outline multidisciplinary strategies to optimize the long-term care of patients with advanced BCC who are on an immunotherapeutic approach.

Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.